ReviewFrontiers in cellular and infection microbiology2012
Shiga toxin in enterohemorrhagic E.coli: regulation and novel anti-virulence strategies.
Review in Frontiers in cellular and infection microbiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
80 citing papers in PubMed, 158 citations in OpenAlex.
- High-throughput transposon sequencing identifies HprR as a key regulator of the LEE operon and virulence inVirulence · 2026Article
- Milk-derived peptone reduces EHEC virulence by inhibiting the type III secretion system.Virulence · 2026Article
- Shiga toxin-centered pathophysiology defines the therapeutic limits of enterohemorrhagic Escherichia coli infection.Archives of microbiology · 2026Review
- Gut Bacteria: A Beneficial Symbiosis or a Hidden Threat? Investigating the Dual Role of Bacteria in Gastrointestinal Diseases.Current microbiology · 2026Review
- RTX-family toxin EhxA drives morphological remodeling and thrombogenesis in RBCs during enterohemorrhagicScience advances · 2026Article
- The Effect of Mitomycin C on Induction of Shiga Toxin Production in Clinical STEC Isolates.Toxins · 2025Article
- Snapshots ofiScience · 2025Article
- Bacterial small molecule metabolites implicated in gastrointestinal cancer development.Nature reviews. Microbiology · 2025Review
- What, how, and why? - anti-EHEC phages and their application potential in medicine and food industry.Journal of applied genetics · 2025Review
- The RNA-binding protein ProQ directly binds and regulates virulence genes in enterohemorrhagicFrontiers in cellular and infection microbiology · 2025Article
- Article
- Prevalence Trends of Foodborne PathogensInternational journal of environmental research and public health · 2024Article
- Article
- ThemSphere · 2024Article
- In Vitro Models for Investigating Intestinal Host-Pathogen Interactions.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- Article
- A novel small RNA regulates Locus of Enterocyte Effacement and site-specific colonization of enterohemorrhagicFrontiers in cellular and infection microbiology · 2024Article
- Diversity of Shiga toxin transducing phages inFrontiers in microbiology · 2024Article
- Pathogenomes and virulence profiles of representative big six non-O157 serogroup Shiga toxin-producingFrontiers in microbiology · 2024Article
- Meta-Analysis of the Prevalence of Porcine Zoonotic Bacterial Pathogens in India: A 13-Year (2010-2023) Study.Pathogens (Basel, Switzerland) · 2023Review
20 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Enterohemorrhagic Escherichia coli (EHEC) are responsible for major outbreaks of bloody diarrhea and hemolytic uremic syndrome (HUS) throughout the world. The mortality associated with EHEC infections stems from the production and release of a potent Shiga toxin (Stx) by these bacteria. Stx induces cell death in endothelial cells, primarily in the urinary tract, causing HUS. Stx was first described in Shigella dysenteriae serotype I by Kiyoshi Shiga and was discovered later in EHEC. Multiple environmental cues regulate the expression of Stx, including temperature, growth phase, antibiotics, reactive oxygen species (ROS), and quorum sensing. Currently, there is no effective treatment or prophylaxis for HUS. Because antibiotics trigger Stx production and their use to treat EHEC infections is controversial, alternative therapeutic strategies have become the focus of intense research. One such strategy explores quorum sensing inhibitors as therapeutics. These inhibitors target quorum sensing regulation of Stx expression without interfering with bacterial growth, leading to the hypothesis that these inhibitors impose less selective pressure for bacteria to develop drug resistance. In this review, we discuss factors that regulate Stx production in EHEC, as well as novel strategies to prevent and/or minimize the development of HUS in infected subjects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.